Bispecific Antibody Development: Upstream Challenges and Strategies

As drug developers focus on identifying novel disease targets and biological mechanisms to look for more potent and effective therapeutics, biological pipelines are evolving from standard antibody formats to next-generation biologics such as bispecific antibodies (bsAbs). However, these molecules are often difficult to express and it is a challenge to develop productive processes. There is a real need for an expression platform that can keep pace with these requirements.

In this GEN webinar, Dr. Jizu Yi will share his experiences on key upstream challenges for the expression of YBODY^® and CHECKBODY^® based bsAbs. Dr. Yi will discuss how his lab successfully developed strategies using the GS Xceed^® Expression System to construct cell lines with high productivity and product quality in a short time span—concluding with how his organization managed to control the level of impurities during manufacturing.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.